ATE381626T1 - Genetische diagnose zur feststellung von qt- verlängerungen als unerwünschte reaktion auf arzneimittel - Google Patents

Genetische diagnose zur feststellung von qt- verlängerungen als unerwünschte reaktion auf arzneimittel

Info

Publication number
ATE381626T1
ATE381626T1 AT01926956T AT01926956T ATE381626T1 AT E381626 T1 ATE381626 T1 AT E381626T1 AT 01926956 T AT01926956 T AT 01926956T AT 01926956 T AT01926956 T AT 01926956T AT E381626 T1 ATE381626 T1 AT E381626T1
Authority
AT
Austria
Prior art keywords
genes
prolonged
adverse reaction
genetic
prolongation
Prior art date
Application number
AT01926956T
Other languages
English (en)
Inventor
Raymond Woosley
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of ATE381626T1 publication Critical patent/ATE381626T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01926956T 2000-04-13 2001-04-13 Genetische diagnose zur feststellung von qt- verlängerungen als unerwünschte reaktion auf arzneimittel ATE381626T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19691600P 2000-04-13 2000-04-13

Publications (1)

Publication Number Publication Date
ATE381626T1 true ATE381626T1 (de) 2008-01-15

Family

ID=22727270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01926956T ATE381626T1 (de) 2000-04-13 2001-04-13 Genetische diagnose zur feststellung von qt- verlängerungen als unerwünschte reaktion auf arzneimittel

Country Status (5)

Country Link
US (1) US7179597B2 (de)
EP (1) EP1290220B1 (de)
AT (1) ATE381626T1 (de)
DE (1) DE60131970T2 (de)
WO (1) WO2001079554A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339879A4 (de) * 2001-06-05 2004-12-29 Genaissance Pharmaceuticals Verfahren zum identifizieren von polymorphismen in cyp2d6
US7192752B2 (en) 2002-12-20 2007-03-20 Acea Biosciences Real time electronic cell sensing systems and applications for cell-based assays
US8263375B2 (en) 2002-12-20 2012-09-11 Acea Biosciences Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology
US10551371B2 (en) 2003-11-10 2020-02-04 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function
US10215748B2 (en) 2002-12-20 2019-02-26 Acea Biosciences, Inc. Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways
US10539523B2 (en) 2002-12-20 2020-01-21 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties
US11346797B2 (en) 2002-12-20 2022-05-31 Agilent Technologies, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
CA2582022C (en) 2004-09-30 2021-05-18 Vanda Pharmaceuticals, Inc. Methods for the administration of iloperidone
CA2629155A1 (en) * 2005-11-10 2007-05-24 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
US20080140371A1 (en) * 2006-11-15 2008-06-12 General Electric Company System and method for treating a patient
CA2723223C (en) 2008-05-05 2017-06-06 Acea Biosciences, Inc. Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution
WO2010054639A2 (de) * 2008-11-13 2010-05-20 Eucro European Contract Research Gmbh & Co. Kg Verfahren zum sammeln von mundschleimhautzellen und/oder -zellfragmenten
US8321151B2 (en) 2008-12-30 2012-11-27 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8315815B2 (en) 2008-12-30 2012-11-20 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8073632B2 (en) * 2008-12-30 2011-12-06 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
EP2417266B1 (de) 2009-04-06 2016-03-09 Vanda Pharmaceuticals Inc. Verfahren zur prognose einer prädisposition für qt-verlängerung
WO2010117931A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of treatment based on polymorphisms of the kcnq1 gene
JP5692872B2 (ja) 2009-04-06 2015-04-01 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｂａｉ遺伝子の配列又はその産物に基づいてｑｔ延長に対する素因を予測する方法
US9074256B2 (en) 2009-04-06 2015-07-07 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to QT prolongation
KR101251538B1 (ko) 2009-04-17 2013-04-08 (주)아벨리노 아벨리노 각막이상증 진단용 프라이머
WO2011146531A1 (en) * 2010-05-18 2011-11-24 Acea Biosciences, Inc Data analysis of impedance-based cardiomyocyte-beating signals as detected on real-time cell analysis (rtca) cardio instruments
KR101125212B1 (ko) 2010-10-01 2012-03-21 (주)아벨리노 아벨리노 각막이상증 진단용 시스템
WO2012149406A2 (en) * 2011-04-29 2012-11-01 Mayo Foundation For Medical Education And Research Assessing and treating humans with long qt syndrome
KR20220100079A (ko) * 2013-03-15 2022-07-14 아벨리노 랩 유에스에이, 인크. 대립유전자 검출을 위한 게놈 dna 주형의 개선된 단리 방법
US10889850B2 (en) 2013-03-15 2021-01-12 Avellino Lab Usa, Inc. Methods for improved isolation of genomic DNA templates for allele detection
AU2014348279B2 (en) 2013-11-15 2021-02-18 Avellino Lab Usa, Inc. Methods for multiplex detection of alleles associated with ophthalmic conditions
DE102014209627B3 (de) * 2014-05-21 2015-10-29 Cytocentrics Bioscience Gmbh In-Vitro-Diagnostik für die modellgestützte Therapieplanung
EP3374502B1 (de) 2015-11-13 2021-10-27 Avellino Lab USA, Inc. Verfahren zur behandlung von hornhautdystrophien
US12066428B2 (en) 2015-11-20 2024-08-20 Agilent Technologies, Inc. Cell-substrate impedance monitoring of cancer cells
KR101920994B1 (ko) * 2016-06-14 2018-11-21 서울대학교산학협력단 식물의 수액 유속 측정용 마이크로 니들 프로브 장치 및 이를 이용한 식물의 수액 유속 측정 방법
CN110582569B (zh) 2017-03-03 2024-04-02 安捷伦科技有限公司 用于iPSC和ESC衍生的心肌细胞的功能成熟的方法和系统
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
USD941488S1 (en) 2020-02-07 2022-01-18 Agilent Technologies, Inc. Instrument for analyzing biological cells
US20210301245A1 (en) 2020-03-29 2021-09-30 Agilent Technologies, Inc. Systems and methods for electronically and optically monitoring biological samples

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599673A (en) * 1995-03-09 1997-02-04 University Of Utah Research Foundation Long QT syndrome genes
US6277978B1 (en) * 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
US6432639B1 (en) 1997-09-10 2002-08-13 Dna Sciences Laboratories, Inc. Isolated CYP3A4 nucleic acid molecules and detection methods
US6207383B1 (en) * 1998-07-27 2001-03-27 University Of Utah Research Foundation Mutations in and genomic structure of HERG—a long QT syndrome gene

Also Published As

Publication number Publication date
DE60131970D1 (de) 2008-01-31
WO2001079554A1 (en) 2001-10-25
EP1290220A1 (de) 2003-03-12
EP1290220B1 (de) 2007-12-19
DE60131970T2 (de) 2008-12-11
EP1290220A4 (de) 2004-09-22
US7179597B2 (en) 2007-02-20
US20030211500A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
ATE381626T1 (de) Genetische diagnose zur feststellung von qt- verlängerungen als unerwünschte reaktion auf arzneimittel
Li et al. Association analysis of the dopamine D4 gene exon III VNTR and heroin abuse in Chinese subjects
Liu et al. Evidence for a putative bipolar disorder locus on 2p13–16 and other potential loci on 4q31, 7q34, 8q13, 9q31, 10q21–24, 13q32, 14q21 and 17q11–12
Marsh Pyrosequencing® applications
Kohn et al. Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects
Sagvolden et al. Behavioral and genetic evidence for a novel animal model of Attention-Deficit/Hyperactivity Disorder Predominantly Inattentive Subtype
ATE239907T1 (de) Ein system für zellbasierte reihenuntersuchungen
Crisafulli et al. Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics
Umair et al. First direct evidence of involvement of a homozygous loss‐of‐function variant in the EPS15L1 gene underlying split‐hand/split‐foot malformation
Bis et al. Uniparental disomy determined by whole‐exome sequencing in a spectrum of rare motoneuron diseases and ataxias
Scantamburlo et al. Allele drop out conferred by a frequent CYP2D6 genetic variation for commonly used CYP2D6* 3 genotyping assays
Becker et al. Evidence for differences in DNA methylation between Germans and Japanese
Hopfer et al. A genome-wide scan for loci influencing adolescent cannabis dependence symptoms: evidence for linkage on chromosomes 3 and 9
Linsel-Nitschke et al. Genetic variation in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) is associated with myocardial infarction in the German population
Ben et al. Multiplex SNaPshot—a new simple and efficient CYP2D6 and ADRB1 genotyping method
Koo et al. Pharmacogenetics approach to therapeutics.
Morling PCR in forensic genetics
Tomita-Mitchell et al. Single nucleotide polymorphism spectra in newborns and centenarians: identification of genes coding for rise of mortal disease
DE60036750D1 (de) Verfahren zur Abschätzung der Sensitivität für Osteoporose-Medikamente
Tang et al. Validation of a large custom-designed pharmacogenomics panel on an array genotyping platform
Yalcıntepe et al. The CYP4502D6* 4 and* 6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients
FR2793809B1 (fr) Procede d'analyse de la predisposition genetique d'un patient a au moins une maladie et amplification adaptee a un tel procede
Philippe et al. Analysis of ten candidate genes in autism by association and linkage
Izzi et al. Sequencing of the GRIK1 gene in patients with juvenile absence epilepsy does not reveal mutations affecting receptor structure
Scionti et al. Tools in pharmacogenomics biomarker identification for cancer patients

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties